Literature DB >> 18436278

B-cell non-Hodgkin lymphomas in Uganda: an immunohistochemical appraisal on tissue microarray.

Lynnette K Tumwine1, Cristina Campidelli, Simona Righi, Sophia Neda, Wilson Byarugaba, Stefano A Pileri.   

Abstract

The most common non-Hodgkin lymphomas in Uganda are neoplasms of B-cell derivation. The field of B-cell lymphoma immunophenotype has rapidly progressed because of the increasing availability of markers applicable to routine sections. Although the latter have allowed the identification of distinctive lymphoma entities in the developed countries, such approach has not yet been used in Uganda. One hundred twenty-nine formalin-fixed, paraffin-embedded tissue samples from the Department of Pathology of Makerere University were used for tissue micro-array (TMA) construction. Four-micrometer-thick sections were cut from TMAs and stained with hematoxylin and eosin and Giemsa. They were also used for immunohistochemistry and in situ hybridization. According to morphology and immunohistochemistry, lymphoid neoplasms were classified as Burkitt's lymphoma (BL) (95 cases), diffuse large B-cell lymphoma (19 cases), mantle cell lymphoma (4 cases), and B-cell lymphoblastic lymphoma (1 case). In BL, a homogeneous phenotype (CD10(+), Bcl-6(+), Bcl-2(-), MUM1/IRF4-, and Ki-67 approximately 100%) and a stable Epstein-Barr virus integration were found. A distinctive and unusual feature was the frequent plasma cellular differentiation, along with the positivity for CD30 and CD138 (recorded in 35 and 43 cases, respectively). According to our findings, most non-Hodgkin B-cell tumors in Uganda are endemic BLs followed by diffuse large B-cell lymphomas. The rest consist of rare but clinically important entities such as mantle cell lymphoma and B-cell lymphoblastic lymphoma. The availability of TMAs and immunohistochemistry has enabled us to precisely categorize tumors that have so far been diagnosed in Uganda as "high-grade/aggressive" lymphomas on the basis of cell morphology alone.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18436278     DOI: 10.1016/j.humpath.2007.10.025

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  10 in total

1.  Accuracy of Burkitt lymphoma diagnosis in constrained pathology settings: importance to epidemiology.

Authors:  Martin D Ogwang; Weiqiang Zhao; Leona W Ayers; Sam M Mbulaiteye
Journal:  Arch Pathol Lab Med       Date:  2011-04       Impact factor: 5.534

2.  EBV-Positive Grey Zone Lymphoma in an HIV Infected Man from Kampala, Uganda: Case Report.

Authors:  Lynette K Tumwine; Jackson Orem; Leona W Ayers
Journal:  Int J Med Pharm Case Reports       Date:  2014-11-15

3.  New developments in the pathology of malignant lymphoma: a review of the literature published from May to July 2008.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2008-09       Impact factor: 0.196

4.  EBV, HHV8 and HIV in B cell non Hodgkin lymphoma in Kampala, Uganda.

Authors:  Lynnette K Tumwine; Jackson Orem; Patrick Kerchan; Wilson Byarugaba; Stefano A Pileri
Journal:  Infect Agent Cancer       Date:  2010-06-30       Impact factor: 2.965

5.  BCL6, MUM1, and CD10 expression in mantle cell lymphoma.

Authors:  Gabriela Gualco; Lawrence M Weiss; William J Harrington; Carlos E Bacchi
Journal:  Appl Immunohistochem Mol Morphol       Date:  2010-03

6.  Agreement between diagnoses of childhood lymphoma assigned in Uganda and by an international reference laboratory.

Authors:  Jackson Orem; Sven Sandin; Caroline E Weibull; Michael Odida; Henry Wabinga; Edward Mbidde; Fred Wabwire-Mangen; Chris Jlm Meijer; Jaap M Middeldorp; Elisabete Weiderpass
Journal:  Clin Epidemiol       Date:  2012-12-14       Impact factor: 4.790

7.  Molecular profiling of aggressive lymphomas.

Authors:  Maura Rossi; Maria Antonella Laginestra; Anna Gazzola; Maria Rosaria Sapienza; Stefano A Pileri; Pier Paolo Piccaluga
Journal:  Adv Hematol       Date:  2011-11-24

8.  Clinicopathological study of sporadic Burkitt lymphoma in children.

Authors:  Hui Huang; Zhi-Liang Liu; Hua Zeng; Shou-Hua Zhang; Chuan-Sheng Huang; Hong-Yan Xu; Yan Wu; Song-Tao Zeng; Feng Xiong; Wen-Ping Yang
Journal:  Chin Med J (Engl)       Date:  2015-02-20       Impact factor: 2.628

9.  pRb2/p130 protein expression and RBL2 mutation analysis in Burkitt lymphoma from Uganda.

Authors:  Sam Kalungi; Solrun J Steine; Henry Wabinga; Leif Bostad; Anders Molven
Journal:  BMC Clin Pathol       Date:  2009-08-19

10.  Immunohistochemical and other prognostic factors in B cell non Hodgkin lymphoma patients, Kampala, Uganda.

Authors:  Lynnette K Tumwine; Claudio Agostinelli; Cristina Campidelli; Emmanuel Othieno; Henry Wabinga; Simona Righi; Brunangelo Falini; Pier Paolo Piccaluga; Wilson Byarugaba; Stefano A Pileri
Journal:  BMC Clin Pathol       Date:  2009-12-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.